Increased expression of FOXC2 has been linked to oestrogen receptor negative basal‐like breast carcinoma 12 and survival in various cancer types 21, 22, 23, 24, 25, 26, but survival data for FOXC2 has not yet been presented in prostate cancer. Here, FOXC2 is linked to prostate cancer.